Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882770 | 0.93 | ALOX12 (0.54) | ALOX12ALOX15GAAMEN1KMT2A | |
| SCHEMBL4884535 | 0.89 | MEN1 (0.52) | ALOX12ALOX15GAAMEN1KMT2A | |
| SCHEMBL4876364 | 0.88 | MEN1 (0.51) | ALOX12ALOX15GAAMEN1KMT2A | |
| SCHEMBL4885229 | 0.83 | MEN1 (0.48) | ALOX12ALOX15GAAMEN1KMT2A | |
| SCHEMBL5271241 | 0.80 | HSP90AA1 (0.49) | ALOX12ALOX15GAAMEN1KMT2A | |
| SCHEMBL4877768 | 0.80 | MEN1 (0.45) | ALOX12ALOX15GAAMEN1KMT2A | |
| SCHEMBL4883675 | 0.78 | MEN1 (0.76) | ALOX12ALOX15GAAMEN1KMT2A | |
| SCHEMBL4890060 | 0.77 | MAPT (0.58) | ALOX12ALOX15GAAMEN1KMT2A | |
| SCHEMBL4881255 | 0.77 | HSP90AA1 (0.37) | ALOX12ALOX15GAAMEN1KMT2A | |
| SCHEMBL4876579 | 0.76 | MAPT (0.52) | ALOX12ALOX15GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090880-A1 | 3-(2-Hydroxyphenyl) Pyrazoles and Thier Use as Hsp90 Modulators | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-04-17 | — | — | US | claimed |
| EP-1799649-A1 | 3-(2-HYDROXYPHENYL) PYRAZOLES AND THEIR USE AS HSP90 MODULATORS | Merck Patent GmbH (DE) | 2007-06-27 | — | — | EP | claimed |
| WO-2006039977-A1 | 3-(2-HYDROXYPHENYL) PYRAZOLES AND THEIR USE AS HSP90 MODULATORS | MERCK PATENT GMBH (DE) | 2006-04-20 | — | — | WO | claimed |
| EP-1799649-B1 | 3-(2-HYDROXYPHENYL) PYRAZOLES AND THEIR USE AS HSP90 MODULATORS | MERCK PATENT GMBH (DE) | 2014-06-25 | — | — | EP | disclosed |
| US-20120053220-A1 | NOVEL LIPOXYGENASE INHIBITORS AS NEUROPROTECTIVE AGENTS | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053220-A1 | NOVEL LIPOXYGENASE INHIBITORS AS NEUROPROTECTIVE AGENTS | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053220-A1 | NOVEL LIPOXYGENASE INHIBITORS AS NEUROPROTECTIVE AGENTS | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2009017825-A2 | NOVEL LIPOXYGENASE INHIBITORS AS NEUROPROTECTIVE AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080090880-A1 | 3-(2-Hydroxyphenyl) Pyrazoles and Thier Use as Hsp90 Modulators | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053220-A1 | NOVEL LIPOXYGENASE INHIBITORS AS NEUROPROTECTIVE AGENTS | ALOX15B, ALOX12, ALOX15 | ALOX12 2/4885ALOX15 3/4885GAA 1196/4885 |
| US-20080090880-A1 | 3-(2-Hydroxyphenyl) Pyrazoles and Thier Use as Hsp90 Modulators | HSP90AB1, HSP90AA1, HSP90AB2P | ALOX12 4239/4885ALOX15 4331/4885GAA 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.